WO2006061650A3 - Methods, products and uses involving platelets and/or the vasculature - Google Patents
Methods, products and uses involving platelets and/or the vasculature Download PDFInfo
- Publication number
- WO2006061650A3 WO2006061650A3 PCT/GB2005/004764 GB2005004764W WO2006061650A3 WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3 GB 2005004764 W GB2005004764 W GB 2005004764W WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- agents
- gpvi
- vasculature
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05849048A EP1824979A2 (en) | 2004-12-10 | 2005-12-12 | Methods, products and uses involving platelets and/or the vasculature |
US11/792,857 US20090130021A1 (en) | 2002-06-07 | 2005-12-12 | Methods, products and uses involving platelets and/or the vasculature |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/009,106 US7531178B2 (en) | 2002-06-07 | 2004-12-10 | Immunoadhesin comprising a glycoprotein VI domain |
US11/009,106 | 2004-12-10 | ||
EP05256993.6 | 2005-11-11 | ||
EP05256993 | 2005-11-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006061650A2 WO2006061650A2 (en) | 2006-06-15 |
WO2006061650A3 true WO2006061650A3 (en) | 2006-08-17 |
Family
ID=36337522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/004764 WO2006061650A2 (en) | 2002-06-07 | 2005-12-12 | Methods, products and uses involving platelets and/or the vasculature |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1824979A2 (en) |
WO (1) | WO2006061650A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2007091719A1 (en) * | 2006-02-07 | 2009-07-02 | 持田製薬株式会社 | Anti-GPVI antibody combination therapy and novel pharmaceutical use |
WO2007116779A1 (en) | 2006-03-31 | 2007-10-18 | Mochida Pharmaceutical Co., Ltd. | Novel platelet activation marker and method for determination thereof |
MX2009013004A (en) | 2007-06-01 | 2010-01-20 | Univ Maryland | Immunoglobulin constant region fc receptor binding agents. |
JP2011518203A (en) * | 2008-04-22 | 2011-06-23 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Method for preventing and treating cancer by GPVI inhibition |
CA2764449A1 (en) * | 2009-06-03 | 2010-12-09 | Regado Biosciences, Inc. | Nucleic acid modulators of glycoprotein vi |
US8889645B2 (en) | 2009-06-03 | 2014-11-18 | Regado Biosciences, Inc. | Nucleic acid modulators of glycoprotein VI |
US8889646B2 (en) | 2009-06-03 | 2014-11-18 | Regado Biosciences, Inc. | Nucleic acid modulators of glycoprotein VI |
US9259485B2 (en) | 2009-07-30 | 2016-02-16 | Fujifilm Corporation | Kidney-imaging agent comprising recombinant gelatin |
EP2336188A1 (en) * | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
EP2397495A1 (en) * | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
EP2513147B1 (en) * | 2009-12-18 | 2016-07-20 | Sanofi | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
BR112013002074B1 (en) | 2010-07-28 | 2021-09-14 | Gliknik Inc | HOMODIMERIC COMPOUND, DIMER OR MULTIMER OF A HIGHER ORDER OF HOMODIMERIC COMPOUND, COMPOSITION, COMPOUND, MULTIMER AND USES THEREOF |
US10468565B2 (en) | 2012-06-11 | 2019-11-05 | Cree, Inc. | LED package with multiple element light source and encapsulant having curved and/or planar surfaces |
AU2013305885B2 (en) | 2012-08-20 | 2017-12-21 | Gliknik Inc. | Molecules with antigen binding and polyvalent Fc gamma receptor binding activity |
WO2017214321A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
JP2020500856A (en) | 2016-12-09 | 2020-01-16 | グリックニック インコーポレイテッド | Method for treating inflammatory disease using polyvalent FC compound |
PE20191354A1 (en) | 2016-12-09 | 2019-10-01 | Gliknik Inc | MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER |
CN108918564B (en) * | 2018-08-09 | 2021-02-02 | 陕西延长石油(集团)有限责任公司研究院 | Analysis method suitable for shale mineral component quantification |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080968A1 (en) * | 2001-04-09 | 2002-10-17 | Millennium Pharmaceuticals, Inc. | Glycoprotein vi and uses thereof |
WO2003008454A2 (en) * | 2001-07-18 | 2003-01-30 | Merck Patent Gmbh | Glycoprotein vi fusion proteins |
WO2003104282A2 (en) * | 2002-06-07 | 2003-12-18 | Procorde Gmbh | Immunoadhesin comprising a glycoprotein vi domain |
WO2005007674A2 (en) * | 2003-07-11 | 2005-01-27 | Molecular Innovations | Anti-human vitronectin antibody and methods for making the same |
WO2005054294A2 (en) * | 2003-12-03 | 2005-06-16 | Trigen Gmbh | Inhibitors of glycoprotein vi based on monoclonal antibody hgp 5c4 |
-
2005
- 2005-12-12 EP EP05849048A patent/EP1824979A2/en not_active Withdrawn
- 2005-12-12 WO PCT/GB2005/004764 patent/WO2006061650A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080968A1 (en) * | 2001-04-09 | 2002-10-17 | Millennium Pharmaceuticals, Inc. | Glycoprotein vi and uses thereof |
WO2003008454A2 (en) * | 2001-07-18 | 2003-01-30 | Merck Patent Gmbh | Glycoprotein vi fusion proteins |
WO2003104282A2 (en) * | 2002-06-07 | 2003-12-18 | Procorde Gmbh | Immunoadhesin comprising a glycoprotein vi domain |
WO2005007674A2 (en) * | 2003-07-11 | 2005-01-27 | Molecular Innovations | Anti-human vitronectin antibody and methods for making the same |
WO2005054294A2 (en) * | 2003-12-03 | 2005-06-16 | Trigen Gmbh | Inhibitors of glycoprotein vi based on monoclonal antibody hgp 5c4 |
Non-Patent Citations (6)
Title |
---|
CIERNIEWSKI C ET AL: "Anti-(Arg-Gly-Asp-Ser) antibody and its interaction with fibronectin, fibrinogen and platelets", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 177, no. 1, October 1988 (1988-10-01), pages 109 - 115, XP002099824, ISSN: 0014-2956 * |
GRÜNER S ET AL: "Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 105, no. 4, 15 February 2005 (2005-02-15), pages 1492 - 1499, XP002375721, ISSN: 0006-4971 * |
SCHULZ CHRISTIAN ET AL: "Glycoprotein VI mediates platelet adhesion to endothelial cells in vivo", CIRCULATION, vol. 112, no. 17, Suppl. S, October 2005 (2005-10-01), & 78TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 13 -16, 2005, pages U93, XP009067061, ISSN: 0009-7322 * |
SMETHURST PETER A ET AL: "Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody.", BLOOD, vol. 103, no. 3, 1 February 2004 (2004-02-01), pages 903 - 911, XP002383117, ISSN: 0006-4971 * |
WU YA-PING ET AL: "Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.", BLOOD. 15 AUG 2004, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1034 - 1041, XP002383118, ISSN: 0006-4971 * |
YANG C H ET AL: "Inhibition of RPE cell-mediated matrix adhesion and collagen gel contraction by crovidisin, a collagen-binding snake venom protein.", CURRENT EYE RESEARCH. NOV 1997, vol. 16, no. 11, November 1997 (1997-11-01), pages 1119 - 1126, XP009067064, ISSN: 0271-3683 * |
Also Published As
Publication number | Publication date |
---|---|
EP1824979A2 (en) | 2007-08-29 |
WO2006061650A2 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006061650A3 (en) | Methods, products and uses involving platelets and/or the vasculature | |
CA2726087A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
WO2007117381A3 (en) | 2 -aminopyridine analogs as glucokinase activators | |
WO2008157733A3 (en) | Fibrin gel for controlled release of pdgf and uses thereof | |
EP2319925A3 (en) | Therapeutic uses of inhibitors of RTP801 | |
WO2007005879A3 (en) | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress | |
WO2009134776A3 (en) | Dual variable domain immunoglobulins and uses thereof | |
WO2009149185A3 (en) | Dual variable domain immunoglobulins and uses thereof | |
WO2007040650A3 (en) | Apoptosis promoters | |
WO2007053189A3 (en) | Compositions and methods for altering immune function | |
ATE473636T1 (en) | FOODS CONTAINING PROBIOTIC AND ISOLATED BETA-GLUCAN AND METHOD OF USE THEREOF | |
TW200606177A (en) | Glycoprotein VI antibodies and methods thereof | |
WO2006002262A3 (en) | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder | |
WO2006122046A3 (en) | Vascular disease therapies | |
WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
WO2007084684A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
WO2008029169A3 (en) | Method of treating respiratory disorders | |
WO2006102061A3 (en) | Methods of decreasing calcification | |
WO2008003943A3 (en) | Inhibition of alpha-synuclein aggregation | |
WO2007068750A3 (en) | Immunoglobulins directed against nogo | |
WO2007135571A3 (en) | Blood group antigens of different types for diagnostic and therapeutic applications | |
WO2006012504A3 (en) | Compounds and methods for treatment of thrombosis | |
WO2008127654A3 (en) | Methods and compositions for intra-articular coagulation proteins | |
WO2006131512A3 (en) | Anti-thrombotic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005849048 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005849048 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11792857 Country of ref document: US |